HDAC11 and hepatocellular carcinoma: The result suggested that drug metabolism cytochrome P450 pathway was significantly enriched in HDAC11-low expression group, indicating that HDAC11 might promote HCC cell sorafenib resistance by inactivation of drug metabolism cytochrome P450 pathway, which has been confirmed to be involved in drug metabolism in liver (Almazroo et al., 2017; Fuscoe et al., 2020).